NATRIY GLYUKOZA KOTRANSPORTERINING 2-TUR INGIBITORLARI BILAN O‘TKAZILGAN KLINIK SINOVLARNI KO‘RIB CHIQISH
##article.subject##:
SGLT2 ingibitorlari, antiremodelirlanuvchi ta'siri, yurak etishmovchiligi, miokard infarkti, surunkali buyrak kasalligi, glomerulyar filtratsiya tezligi, antigiperglikemik ta'sir##article.abstract##
Ushbu maqolada asosan 2-tur qandli diabetni davolash uchun ishlatiladigan dorilar sinfi bo'lgan SGLT2 ingibitorlarining samaradorligi va xavfsizligini baholovchi klinik sinovlar umumlashtiriladi va tahlil qilinadi. Maqola EMMY, EMPAREG OUTCOME, DAPA-HF, EMPULSE, SOLOIST-WHF va EMPACT-MI kabi bir nechta asosiy tadqiqotlarni o'z ichiga oladi, ular SGLT2 ingibitorlarining yurak-qon tomir kasalliklarini kamaytirish va buyrak funktsiyasini yaxshilashdagi foydali ta'sirini ta'kidlaydi. Maqolada SGLT2 ingibitorlarini nafaqat qandli diabetni 2-turini davolashda, balki yurak yetishmovchiligi va surunkali buyrak kasalliklarini davolashda ham qo‘llash haqida so‘z boradi. Mualliflar SGLT2 ingibitorlari 2-tur qandli diabet va unga bog'liq bo'lgan asoratlarni davolashda sezilarli foyda keltiradi, shuningdek, kengroq terapevtik sohalarda ham qo`llash mumkin degan xulosaga kelishadi. Ushbu maqola zamonaviy klinik amaliyotda SGLT2 ingibitorlarining o'zgaruvchan rolini tushunish uchun muhim va davom etayotgan tadqiqotlar haqida qimmatli tushunchalarni beradi.
Библиографические ссылки
Bagriy A.E., Efremenko V. A., Golodnikov I.A., Druzhinkina N.V., Trandafilova M.N. Federal state budgetary educational institution of high school donetsk state medical university named after m. Gorky moh rf department of internal medicine no. 2. P-1-2.
N.A. Shumilova, S.I. Pavlova Acta medicine Eurasica. 2019. No. 1 UDC 615.272.3 BBK 52.81 http://acta-medica-eurasica.ru/single/2019/1
Mkrtumyan A.M., Egshatyan L.E. New non-insulin-dependent approach to the treatment of type 2 diabetes mellitus. Dapagliflozin: results of clinical trials // Effective pharmacotherapy. 2015. No. 11. P. 17–25.
Shestakova M.V., Sukhareva O.Yu. Gliflozins: features of hypoglycemic action and non-glycemic effects of a new class of drugs // Clinical Pharmacology and Therapy. 2016. Vol. 25, No. 2. P. 65–71.
Rieg T., Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia, 2018, vol. 61, P. 2079–2086.
Scheen A. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment // Drugs. 2015. Vol. 75. No. 1. P. 33–59.
Ferrannini E., Muscelli E., Frascerra S. et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients // J. Clin. Invest. 2014. Vol. 124. No. 2. P. 499–508.
Tripolt NJ, Kolesnik E, Pferschy PN, Verheyen N, Ablasser K, Sailer S, et al. Impact of EMpagliflozin on cardiac function and biomarkers of heart failure in patients with acute MYocardial infarction—the EMMYtrial. American Heart Journal.2020; 221: P 39–47.
Von Lewinski D, Kolesnik E, Tripolt NJ, Pferschy PN, Benedikt M, Wallner M, et al. Empagliflozin in acute myocardial infarctiontion: the EMMY trial. European Heart Journal. 2022; 43: P 4421-4432.
Martin Benedikt, Ewald Kolesnik, Harald Sourij, Dirk von Lewinski. SGLT2 Inhibition in Acute Myocardial Infarction—A Comprehensive Review. Rev. Cardiovasc. Med. 2023, 24(2), P 32. https://doi.org/10.31083/j.rcm2402032
Lecour S, Andreadou I, Bøtker HE, Davidson SM, Heusch G, Ruiz- Meana M et al . Iimproving Preclinical Assessment of Car dioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Research in Cardiology. 2021; 116: P 52.
Heusch G. Critical Issues for the Translation of Cardioprotection. Circulation Research. 2017;120: P 1477–1486.
Hausenloy D.J.,Yellon D.M. Myocardial ischemia -reperfusionin jury: a neglected therapeutic target. Journal of Clinical Investiation 2013;123: P 92–100.
Kosiborod M, Birkeland KI, Cavender MA, Fu AZ, Wilding JP, Khunti K, et al. Rates of myocardial infarction and stroke in patients initiating treatment with SGLT2-inhibitors versus other glucose-lowering agents in real-world clinical practice: Results from the CVD- REALstudy.Diabetes, Obesity and Metabolism. 2018; 20: P 1983–1987.
Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L, et al. Sodium-dependent glucose transporters (SGLT) in human ischemic heart: a new potential pharmacological target. International Journal of Cardiology. 2017; 243: P 86–90.
Von Lewinski D, Benedikt M, Tripolt N, Wallner M, Sourij H, Kolesnik E. Can sodium glucose cotransporter 2 (SGLT-2) in inhibitors be beneficial in patients with acute myocardial infarctiontion? Cardiology Polska 2021; 79: P 503–509.
Asensio Lopez MDC, Lax A, Hernandez Vicente A, Saura Guillen E, Hernandez-Martinez A, Fernandez del Palacio MJ, et al. Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status. Scientific Reports. 2020; 10: P 13553.
Baartscheer A, Schumacher CA, Wüst RCI, Fiolet JWT, Stienen GJM, Coronel R, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia 2017; 60: P 568–573.
Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fi olet JWT, Koeman A, et al. Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ ex changer, lowering of cytosolic Na+ and vasodilation. Diabetologia. 2018; 61: P 722–726.
Koyani C N, Plastira I, Sourij H, Hallström S, Schmidt A, Rainer PP, et al. Empagliflozin protects heart from inflammation and energy depletion via AMPK activation. Pharmacological Research. 2020; 158: P 104870.
Santos- Gallego CG, Requena -Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin Ame liorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics. Journal of the American College of Cardiology. 2019; 73: P 1931–1944.
Zhou X ,Jin M, Liu L,Yu Z, Lu X, Zhang H. Trimethylamine N oxide and cardiovascular outcomes in patients with chronic heart failure after myocardial infarction. ESC Heart Failure. 2020; 7:188–193.
Andreadou I, Efentakis P, Balafas E, Togliatto G, Davos CH, Varela A, et al. Empagliflozin Limits Myocardial Infarction in Vivo and Cell Death in Vitro: Role of STAT3, Mitochondria, and Redox Aspects. Frontiers in Physiology. 2017; 8:1077.
Lahnwong S,Palee S, Apaijai N, Sriwichaiin S,Kerdphoo S, Jai Wongkam T,etal. Acute dapagliflozin administration implements cardioprotective effects in rats with cardiac ischemia/reperfusion injury. Cardiovascular Diabetology. 2020; 19:91.
Lee T, Chang N, Lin S. Dapagliflozin, a selective SGLT2 Inhibitor , attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radical Biology and Medicine. 2017;104: 298–310.
The Lancet Diabetes & Endocrinology.Gettingtotheheartofthematter in type 2diabetes. The Lancet Diabetes & Endocrinology. 2015; 3:827.
Ceriello A, Genovese S, Mannucci E, Gronda E. Understanding EMPA-REG OUTCOME. The Lancet Diabetes & Endocrinology. 2015; 3: 929–930.
Gilbert RE, Connelly KA. Understanding EMPA-REG OUT COME. The Lancet Diabetes & Endocrinology. 2015; 3:930931.
Curtain JP, Docherty KF, Jhund PS, Petrie MC, Inzucchi SE, Køber L, et al. Effect of dapagliflozin on ventricular arrhythm mias , resuscitated cardiac arrest, or sudden death in DAPA-HF. European Heart Journal. 2021; 42: 3727–3738.
Clinical Trials.gov. A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart Failure. Available at: https://clinicaltrials.gov/ct2/show/NCT04157751. Accessed: November 2021. 11 GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: A systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016; 388(10053):1459–544.
Voor AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. (2022). DOI:10.1038/s41591-021-01659-1
Biegus J, Voors AA, Collins SP, Kosiborod MN, Teerlink JR, Angermann CE, et al. Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial. Eur Heart J (2023) 44(1):41–50. doi: 10.1093/ eurheartj /ehac530
Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. (2021) 384(2):117–28. doi: 10.1056/nejmoa2030183
James S, Erlinge D, Storey RF, McGuire DK, de Belder M, Eriksson N, et al. Dapagliflozin in myocardial infarction without diabetes or heart failure. N Engl J Med. (2023) 3(2):EVIDoa2300286. doi: 10.1056/EVIDoa2300286
Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC guidelines for the management of acute coronary syndromes. Eur Heart J (2023) 44(38):3720–826. doi: 10.1093/ eurheartj /ehad191
Harrington J, Udell JA, Jones WS, Anker SD, Bhatt DL, Petrie MC, et al. Empagliflozin in patients post myocardial infarction rationale and design of the EMPACT-MI trial. Am Heart J (2022) 253(Mi):86–98. doi: 10.1016/j.ahj.2022.05.010
Rahhal A, Hamamyh T, Chapra A, Zaza KJ, Najim M, Hemadneh M, Faraj H, Kanjo W, Yasin A, Toba H, Mohammed W, Hamad MK, Al-Tikrety N, Baraa Habib M, Awaisu A, Mahfouz A, Alyafei S, Arabi AR, Patel A and Al-Hijji M (2024) Sodium–glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure. Front. Cardiovasc. Med. 11:1383669. https://doi.org/10.3389/fcvm.2024.1383669
Solomon SD, McMurray JJV, Claggett B et al. Dapagliflozin in heart failure with moderately reduced or preserved ejection fraction. N Engl J Med 2022; 387:1089 –98. https :// doi. org /10.1056/ NEJMoa 2206286
Herrington WG, Staplin N, Wanner C, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med 2023 ;388:117–27. https://doi.org/10.1056/NEJMoa2204233
Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT -2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials. Lancet 2022; 400: 757–67. https://doi.org/10.1016/S0140-6736(22)01429-5
SGLT 2 inhibitor meta-analysis investigators. Impact of diabetes on the effects of sodium-glucose cotransporter-2 inhibitors on renal outcomes: a collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400:1788–801. https://doi.org/10.1016/S0140-6736(22)02074-8 .
SGLT2 Inhibitors in CKD and HFpEF: Two Large New Trials and Two New Meta-Analyses February 2023 Br J Cardiol 2023; 30: 7–9 doi : 10.5837 / bjc.2023.003
SGLT -2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials Muthiah Vaduganathan 1 , Kieran F. Docherty 2 Brian L. Claggett 1 , Pardeep S. Jund 2 , Rudolf A de Boer 3 , Adrian F. Hernandez 4 , Silvio E. Inzucchi 5 , Mikhail Nikolaevich Kosiborod 6 , Caroline SP Lam 7 Felipe Martinez 8 , Sanjeev J. Shah 9 Akshay With Desai 1 John J. W. Macmurray 2 Scott D. Solomon 10 PMID : 36041474 - DOI : 10.1016/ S 0140-6736(22)01429-5 .
